Plutzky, Jorge

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 3,236

Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsHealth Promotion and Cardiovascular Prevention

Cited by 1,055

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 988

NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis

Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell

Genomics and Chromatin DynamicsNF-κB Signaling Pathways

Cited by 614

Discontinuation of Statins in Routine Care Settings: A Cohort Study

Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 548

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 463

BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure

Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell

Protein Degradation and InhibitorsGenomics and Chromatin Dynamics

Cited by 406

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

Ryan, D. H., Lingvay, I., Deanfield, J., Kahn, S. E., Barros, E., Burguera, B., Colhoun, H. M., Cercato, C., Dicker, D., Horn, D. B., et al. (2024) · Nature Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 347

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

Fruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 260

Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions

Halter, J. B., Musi, N., McFarland Horne, F., Crandall, J. P., Goldberg, A., Harkless, L., Hazzard, W. R., Huang, E. S., Kirkman, M. S., Plutzky, J., et al. (2014) · Diabetes

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 255

Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design

Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 249

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 238

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial

Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 143

Deletion of the α-Arrestin Protein Txnip in Mice Promotes Adiposity and Adipogenesis While Preserving Insulin Sensitivity

Chutkow, W. A., Birkenfeld, A. L., Brown, J. D., Lee, H.-Y., Frederick, D. W., Yoshioka, J., Patwari, P., Kursawe, R., Cushman, S. W., Plutzky, J., et al. (2010) · Diabetes

Peroxisome Proliferator-Activated ReceptorsAdipokines, Inflammation, and Metabolic Diseases

Cited by 142

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health

Cited by 140

Epigenetic Changes in Diabetes and Cardiovascular Risk

Keating, S. T., Plutzky, J., & El-Osta, A. (2016) · Circulation Research

Epigenetics and DNA MethylationGenomics and Chromatin Dynamics

Cited by 139

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

Nicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 136

Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review

Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 127

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 113

Results of a remotely delivered hypertension and lipid program in more than 10?000 patients across a diverse health care network.

Blood, A. J., Cannon, C. P., Gordon, W. J., Mailly, C., MacLean, T., Subramaniam, S., Tucci, M., Crossen, J., Nichols, H., Wagholikar, K. B., et al. (2023) · JAMA Cardiology

Telemedicine and Telehealth ImplementationBlood Pressure and Hypertension Studies

Cited by 108

Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice

Kiefer, F. W., Neschen, S., Pfau, B., Legerer, B., Neuhofer, A., Kahle, M., Hrabé de Angelis, M., Schlederer, M., Mair, M., Kenner, L., et al. (2011) · Diabetologia

Liver Disease Diagnosis and TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 104

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 64

Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis

Plutzky, J., Garber, A., Falahati, A., Toft, A. D., & Poulter, N. R. (2009) · Canadian Journal of Diabetes

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 33

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins

Bays, H. E., Baum, S. J., Brinton, E. A., Plutzky, J., Hanselman, J. C., Teng, R., & Ballantyne, C. M. (2021) · American Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 25